Table 1.
Patient characteristics
| HCC | BTC | Total | |
|---|---|---|---|
| Number of patients | 56 | 30 | 86 |
| Site | |||
| NIH Clinical Center | 22 (39%) | 23 (77%) | 45 (52%) |
| Georgetown University | 18 (32%) | 1 (3%) | 19 (22%) |
| Massachusetts General Hospital | 7 (13%) | 4 (13%) | 11 (13%) |
| University of California San Francisco | 7 (13%) | 2 (7%) | 9 (10%) |
| Thomas Jefferson University | 2 (4%) | 0 | 2 (2%) |
| Age | |||
| Age at diagnosis (median) | 35–84 (63) | 20–79 (63) | 20–84 (63) |
| Unknown | 8 (14%) | 4 (13%) | 12 (14%) |
| Sex | |||
| Male | 45 (80%) | 18 (60%) | 63 (73%) |
| Female | 11 (20%) | 12 (40%) | 23 (27%) |
| Race | |||
| White | 26 (46%) | 29 (97%) | 55 (64%) |
| Black or African American | 18 (32%) | 0 | 18 (21%) |
| Asian | 7 (13%) | 1 (3%) | 8 (9%) |
| Native Hawaiian or other Pacific Islander | 1 (2%) | 0 | 1 (1%) |
| Other | 2 (4%) | 0 | 2 (2%) |
| Unknown | 2 (4%) | 0 | 2 (2%) |
| Ethnicity | |||
| Hispanic or Latino | 3 (5%) | 1 (3%) | 4 (5%) |
| Not Hispanic or Latino | 53 (96%) | 28 (93%) | 81 (94%) |
| Unknown | 0 | 1 (3%) | 1 (1%) |
| Hepatitis B virus (HBV) status | |||
| No | 43 (77%) | 27 (90%) | 70 (81%) |
| Yes | 13 (23%) | 3 (10%) | 16 (19%) |
| Hepatitis C virus (HCV) status | |||
| No | 28 (50%) | 26 (87%) | 54 (63%) |
| Yes | 27 (48%) | 4 (13%) | 31 (36%) |
| Unknown | 1 (2%) | 0 | 1 (1%) |
| Steatohepatitis | |||
| No | 42 (75%) | 27 (90%) | 69 (80%) |
| Yes | 8 (14%) | 3 (10%) | 11 (13%) |
| Unknown | 6 (11%) | 0 | 6 (7%) |
| Alcohol abuse | |||
| No | 33 (59%) | 28 (93%) | 61 (71%) |
| Yes | 23 (41%) | 2 (7%) | 25 (29%) |
| Cirrhosis | |||
| No | 24 (43%) | 28 (93%) | 52 (60%) |
| Yes | 32 (57%) | 2 (7%) | 34 (40%) |
| Prior treatment | |||
| No | 16 (29%) | 1 (3%) | 17 (20%) |
| Yes | 32 (57%) | 27 (90%) | 59 (69%) |
| Unknown | 8 (14%) | 2 (7%) | 10 (12%) |
| Best RECIST v.1.1 response | |||
| CR | 1 (2%) | 0 | 1 (1%) |
| PR | 6 (11%) | 3 (10%) | 9 (10%) |
| SD | 25 (45%) | 12 (40%) | 37 (43%) |
| PD | 18 (32%) | 12 (40%) | 30 (35%) |
| Non-evaluable | 3 (5%) | 1 (3%) | 4 (6%) |
| Unknown | 3 (5%) | 2 (7%) | 5 (6%) |
| Immunotherapy category | |||
| Single-agent ICI | 15 (27%) | 9 (30%) | 24 (28%) |
| Single-agent ICI with VEGF inhibitor | 13 (23%) | 0 | 13 (15%) |
| Single-agent ICI with targeted therapy | 3 (5%) | 3 (10%) | 6 (7%) |
| Combination ICI | 24 (43%) | 18 (60%) | 42 (49%) |
| Combination ICI with targeted therapy | 1 (2%) | 0 | 1 (1%) |
BTC, biliary tract cancer; HCC, hepatocellular carcinoma; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ICI, immune checkpoint inhibitor; TKI, tyrosine kinase inhibitor.